Newsfeeds - Spark Newswire

3 minute read

FDA
News

Natera Releases New Clinical Data At ESMO 2021 In Gastroesophageal Cancer And Uveal Melanoma

Today, 11:23 AM

Natera, Inc. (NASDAQ:NTRA), a leader in cell-free DNA testing, today announced new data being presented by the company and its collaborators on the use of the Signatera® personalized molecular

NTRA

1 minute read

Earnings

Return on Capital Employed Overview: Natera

By Benzinga Insights

Today, 11:23 AM

After pulling data from Benzinga Pro it seems like during Q2, Natera (NASDAQ:NTRA) brought in sales totaling $142.03 million. However, earnings decreased 82.96%, resulting in a loss of $115.29 million.

NTRA

1 minute read

Natera Q2 Sales Tops Street Estimates On Higher Volumes, Raises FY21 Sales Outlook

By Vandana Singh

Today, 11:23 AM

Natera Inc's (NASDAQ: NTRA) second-quarter revenues jumped 64

NTRA

1 minute read

Natera Q2 EPS $(1.32) Misses $(1.08) Estimate, Sales $142.00M Beat $127.49M Estimate

By Benzinga Newsdesk

Today, 11:23 AM

Natera (NASDAQ:NTRA) reported quarterly losses of $(1.32) per share which missed the analyst consensus estimate of $(1.08) by 22.22 percent. This is a 76 percent decrease over losses of $(0.75) per share from the same

NTRA

7 minute read

The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO

By Shanthi Rexaline

Today, 11:23 AM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4)

ABSI

34 minute read

Earnings Scheduled For August 5, 2021

By Benzinga Insights

Today, 11:23 AM

Companies Reporting Before The Bell • OneSpaWorld Holdings (NASDAQ:OSW) is projected to report quarterly loss at $0.20 per share on revenue of $6.42 million.

AAOI

2 minute read

Movers

Analyzing Natera’s Unusual Options Activity

By Benzinga Insights

Today, 11:23 AM

On Wednesday, shares of Natera (NASDAQ:NTRA) saw unusual options activity. After the option alert, the stock price moved up to $112.96.

NTRA

1 minute read

News

Natera Reports Use Of Signatera As Companion Diagnostic In GlaxoSmithKline’s Phase 3 ZEST Trial For Niraparib In Early-Stage Breast Cancer

By Benzinga Newsdesk

Today, 11:23 AM

-- Natera, Inc. (NASDAQ:NTRA), a pioneer and global leader in cell-free DNA testing, announced that the first patient has been screened in a new phase III trial that uses its personalized, tumor-informed molecular

GSK